<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37591">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617160</url>
  </required_header>
  <id_info>
    <org_study_id>RMC059315ctil</org_study_id>
    <nct_id>NCT02617160</nct_id>
  </id_info>
  <brief_title>Evaluation of Automated Insulin Pump Settings Using the MD-Logic Advise4U</brief_title>
  <official_title>Evaluation of Automated Insulin Pump Settings Using the MD-Logic Pump Advisor- The MD-Logic Advise 4 U- Open Label, Parallel , Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DreaMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pump therapy is gaining popularity as a treatment mode for patients with type 1 diabetes.
      Utilizing pump therapy requires the development and application of a new spectrum of
      theoretical knowledge and practical skills by the patient. Furthermore, occasionally there
      is a need to tailor the pump settings, i.e. the insulin correction factor, carbohydrate
      ratio, basal plan and insulin activity time, in order to optimize and improve glucose
      control. These adjustments are based on collected information including insulin delivery,
      blood glucose measurements, continuous glucose monitoring data, meals and so on. Analyzing
      this multitude of information and data is overwhelming for many of the patients, caregivers
      and health care providers. Unfortunately, not all physicians have the needed expertise to
      fully fulfill this task, and for those who do, it is time consuming. Thus, a summary of the
      data with insulin dose adjustment suggestions is missing. An automated tool for pump setting
      adjustments will improve glycemic control without escalating the burden on patients and the
      health care system. Such advisor can assist the professional team during routine follow-up
      and the patients between visits.

      To address this challenge, the investigators developed the MD-Logic Pump Advisor (MDPA),
      which automatically analyses treatment information, learns patient's needs and accordingly
      suggests adjustments in insulin dosing. The MDPA uses information gathered from glucose
      monitoring, insulin dosing and meal data during daily routine home care. Following a 5
      minute data collection and analysis, the algorithm learns and suggests pump-setting changes
      for optimization of glucose control.

      The objective of the research project, called MD-Logic Advise4U, is to test the MD-Logic
      pump advisor in a clinical study. The study will generate data necessary to address the
      safety, reliability, and efficacy of this algorithm
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of glucose readings within range of 70-180 mg/dl</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose readings below 60 mg/dl</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb A1c levels</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The percentage of glucose readings below 70 mg/dl</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of glucose readings above 240 mg/dl</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of glucose readings above 180</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of unexplained hyperglycemic events</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area above the curve of 180 mg/dl</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the curve of 70 mg/dl</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean sensor blood glucose</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucose variability measured by Standard Deviation (SD)</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of recommendations for changes in settings per patient and per iteration</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of physician override advisor recommendations</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time duration needed for the physician to give his recommendations</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Score in QoL Questionnaire</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diabetes Treatment Satisfaction Score in Diabetes Treatment Satisfaction Questionnaire (DTSQ)</measure>
    <time_frame>Day 90</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>MD Logic Pump Advisor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group-Medical guided recommendations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MD-Logic Pump Advisor</intervention_name>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor</description>
    <arm_group_label>MD Logic Pump Advisor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice</description>
    <arm_group_label>Control Group-Medical guided recommendations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented Type 1 Diabetes for at least 1 year prior to study enrollment

          -  Subjects aged ≥ 10 years and up to 25 years

          -  HbA1c at inclusion ≤ 11%

          -  Insulin pump therapy for at least 4 months

          -  BMI Standard Deviation Score - below the 97th percentile for age

          -  Subjects willing to follow study instructions: measure capillary blood glucose at
             least 4 times a day and use the bolus-wizard feature of the pump.

        Exclusion Criteria:

          -  An episode of diabetic keto-acidosis within the month prior to study entry

          -  Severe hypoglycemia resulting in seizure or loss of consciousness in the month prior
             to enrollment

          -  Concomitant diseases/ treatment that influence metabolic control

          -  Significant diseases /conditions including psychiatric disorders and substance abuse
             that in the opinion of the investigator is likely to affect the subjects ability to
             complete the study or compromise patients safety

          -  Participation in any other interventional study

          -  Known or suspected allergy to trial products

          -  Female subject who is pregnant or planning to become pregnant within the planned
             study duration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Phillip, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Phillip, MD, Prof</last_name>
    <phone>972-3-9253747</phone>
    <email>mosheph@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Hamou, Msc</last_name>
    <phone>972-3-9253778</phone>
    <email>alonah@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schneider Medical Center</name>
      <address>
        <city>Petach- Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe :Phillip, Prof.</last_name>
      <phone>972-3-9253282</phone>
      <email>mosheph@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Alona Hamou, MSc</last_name>
      <phone>972-3-9253778</phone>
      <email>alonah@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Revital Nimri, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tal Oron, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon Demol, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shlomit Shalitin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariel Tenennbaum, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liat De-vries, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liora Lazar, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Avivit Brener, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Bello, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Mouler, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naama Fish, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yael Lebenthal, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 10, 2017</lastchanged_date>
  <firstreceived_date>November 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin Pump Treatment</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Insulin Pump Setting</keyword>
  <keyword>Pump Advisor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
